Table 1 Baseline characteristics of our target and control groups
Study group (n = 85) | Control group (n = 170) | |||
|---|---|---|---|---|
Non DVT | DVT | Non DVT | DVT | |
Number of patients | 74 (87%) | 11 (13%) | 158 (92.9%) | 12 (7.1%) |
Age (mean) | 27–85 (61.9) | 57–84 (68.4) | 25–85 (62.1) | 32–81 (59.7) |
Sex ratio | ||||
Male/Female | 33 (44.6%)/41 (55.4%) | 5 (45.4%)/6 (54.6%) | 71 (44.9%)/86 (55.1%) | 5 (41.6%)/7 (58.4%) |
Fracture location | ||||
Femur | 66 (89.1%) | 11 (100%) | 142 (89.8%) | 11 (91.6%) |
Tibia | 8 (10.9%) | 0 | 16 (10.2%) | 1 (8.4%) |
Type of implant | ||||
Prosthesis | 18 (24.3%) | 2 (18.1%) | 37 (23.4%) | 4 (33.3%) |
Intramedullary nail | 53 (71.6%) | 7 (63.8%) | 112 (70.8%) | 5 (41.6%) |
Plate | 3 (4.1%) | 2 (18.1%) | 9 (5.8%) | 2 (16.7%) |
Tumoral origin | ||||
Metastases | 47 (55.3%) | 8 (72.7%) | 0 | 0 |
Primary tumour | 27 (44.7%) | 3 (27.3%) | 0 | 0 |
Adjuvant therapy | ||||
Radiotherapy | 18 (21.17%) | 6 (54.5%) | 0 | 0 |
Chemotherapy | 15 (17.64%) | 4 (36.3%) | 0 | 0 |
None | 41 | 1 | 158 (100%) | 12 (100%) |
Tromboprophylaxis | ||||
LMWH | 61 (82.7%) | 10 (90.9%) | 129 (81.7%) | 9 (75%) |
Double dose LMWH | 4 (5.5%) | 1 (9.1%) | 9 (5.7%) | 2 (16.6%) |
Rivaroxaban | 4 (5.5%) | 0 | 6 (3.8%) | 0 |
Clopidogrel | 5 (5.9%) | 0 | 14 (8.8%) | 1 (8.4%) |